Is relief in sight? Flu season still brutal but cases are declining.

Influenza activity in the U.S. appears to be peaking and declining in early January: CDC data through Jan. 3 show ~25% (25,357 of 102,518) of tests positive (down from ~32%), wastewater surveillance reported a 37% median concentration drop between Dec. 26 and Jan. 7, and CDC projects declining or likely declining activity in 44 states. The season has produced substantial health burden—approximately 180,000 hospitalizations, 7,400 deaths, and 17 pediatric fatalities so far—and is being driven by an H3N2 mutation (subclade K) that accounted for ~91–92% of recent type A/H3N2 samples and may reduce vaccine effectiveness, although preliminary data show some protection and comparable hospitalization rates to last year in Europe. The CDC’s Jan. 6 changes to childhood vaccine recommendations (limiting universal flu and other childhood vaccine recommendations) add policy uncertainty for pediatric uptake and could affect healthcare utilization and absenteeism in the near term.

Analysis

Market structure: Diagnostics, retail pharmacies and ED-heavy hospitals are the near-term beneficiaries — expect outsize volume for rapid-test makers (Abbott ABT, QuidelOrtho QDEL) and labs (Quest DGX, LabCorp LH) for the next 4–12 weeks; pharmacies (CVS, WBA) pick up vaccine & OTC sales. Vaccine manufacturers (Sanofi SNY, GSK GSK, Moderna MRNA, Pfizer PFE) face mixed dynamics: current H3N2 subclade K reduces 2025–26 shot effectiveness (dampening near-term demand) but increases probability of upgraded 2026–27 orders, favoring manufacturers with flexible capacity. Insurers (UNH, CI) are modestly exposed to higher claim frequency and reserve volatility; travel/leisure (AAL, DAL) are downside-sensitive to prolonged absenteeism.

Risk assessment: Tail risks include a further antigenic shift in subclade K that materially increases hospitalizations (>20% above current CDC projection) or federal intervention on vaccine mandates, creating regulatory and supply shocks. Short-term (days–weeks): elevated ED visits and testing demand; medium (1–3 months): antiviral prescriptions and OTC sales spike; long-term (6–12 months): vaccine reformulation contracts and capacity allocation determine winners. Hidden dependencies: CDC’s Jan 6 change reducing universal childhood vaccine recommendations may lower pediatric uptake (depressing pediatric vaccine revenue) while paradoxically increasing severe-case incidence and testing demand regionally.

Trade implications: Establish small, highly liquid tactical longs: ABT (1.5% position) and DGX (1% position) to capture 4–12 week testing tail; enter 2–3 month call spreads (buy 1–2% notional) on ABT/DGX to limit capital. Pair trade: long QDEL (0.75%) / short DAL (0.75%) to express diagnostics upside vs. travel weakness. Avoid/trim near-term long positions in SNY/GSK until clearer pediatric uptake data; consider 6–12 month long exposure to MRNA or PFE (0.5–1%) as optionality on next-gen flu winners.

Contrarian angles: The market may underprice the impact of CDC guidance — expected fall in pediatric vaccination could temporarily compress vaccine revenues for SNY/GSK but materially increase antiviral and testing demand; that asymmetry favors diagnostics/pharmacy plays over incumbent vaccine-only names. Historical parallel: 2017–18 H3N2 season saw outsized antiviral sales and lab volume for ~3 months — expect a similar concentrated revenue window, then normalization. Catalysts to watch (action triggers): weekly CDC state maps, WasteWaterSCAN median trends, and manufacturer capacity announcements — act within 3–10 days of data shifts.

Key Decisions for Investors

• Establish a 1.5% long position in Abbott Laboratories (ABT) to capture elevated rapid-test and point-of-care demand over the next 4–12 weeks; hedge with a 2–3 month 10–15% OTM call spread to limit capital at risk.
• Initiate a 1.0% long position in Quest Diagnostics (DGX) or LabCorp (LH) to benefit from increased lab throughput; use a 2–3 month call spread sized at 1% notional and scale out if weekly positive test rate stays >20% for two consecutive weeks.
• Enter a pair trade: long QuidelOrtho (QDEL) 0.75% / short Delta Air Lines (DAL) 0.75% to express diagnostics upside versus travel demand risk; unwind if CDC projects national infections declining in 44 states for two consecutive weeks.
• Avoid initiating new near-term core-long positions in Sanofi (SNY) and GSK (GSK) until pediatric vaccine uptake data 30–60 days post-CDC guidance stabilizes; consider a 0.5–1% long in Moderna (MRNA) or Pfizer (PFE) as 6–12 month upside optionality on updated vaccine contracts.
• Reduce discretionary exposure to airlines/cruise operators by 1–2% and rotate into healthcare staples/pharmacy (increase CVS/WBA exposure by 1% combined) if weekly ED flu visit share remains >8% for more than three consecutive weeks.